Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q2 2021 Earnings Presentation
20 slides from Q-linea Ab's earnings presentation, Jul 15, 2021
Slide 1: Future Proof Healthcare – Presentation Q2(21)
FUTURE PROOF HEALTHCARE A sustainable healthcare for a new generation Presentation Q2(21) Jonas Jarvius, CEO Anders Lundin, CFO/IR
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 2nd quarter – Introduction to the company
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 2nd quarter Q-linea is developing disruptive solutions for faster Lead product ASTar® infectious disease diagnostics, first product targeting sepsis Introduction to the company Achieved CE-IVD for first application for AS
Slide 4: Sepsis – a global health crisis
Sepsis – a global health crisis Time to correct treatment critical for patient outcome 4
Slide 5: Why is improved infectious disease diagnostics important?
Why is improved infectious disease diagnostics important? Sepsis AMR Antimicrobial Resistance Leading cause of death in U.S. hospitals1) Has been presented as #1 hospitalization cost in the US with over $24bn “The biggest threat to mankind” yearly3) Rapid diagnostics would reduce Kills >500,000 peop
Slide 6: ASTar – a platform designed to save lifetimes
ASTar – a platform designed to save lifetimes Developed together with our future customers Easy to use Comprehensive • Fully automated • Large antibiotic panel • ~2 min hands-on time • Long concentration • Load-and go workflow ranges • Fastidious and non- fastidious bacteria Fast • Support additiona
Slide 7: Full automation matters: ASTar enables anyone at the lab to load sample anytime
Full automation matters: ASTar enables anyone at the lab to load sample anytime ASTar enables lab personnel to do more in less time Click “start” Scan barcode Add sample Load AST disc Add sample barcode Click “Start run” Source: Company information and webpage 7
Slide 8: Rapid AST & a broad antimicrobial panel matters
Rapid AST & a broad antimicrobial panel matters: ASTar can provide up to 40 hours faster actionable results DAY 1 DAY 2 DAY 3 DAY 4 Plates are streaked CURRENT WORKFLOW Gram Susceptibility Patient to perform a Colony blood draw stain clean culture selection Determination (AST) Optimized Time to Bloo
Slide 9: Rapid AST could help saving lives
Rapid AST could help saving lives One example for Uppsala University Hospital pre-clinical study ASTar was much faster than standard AST method and provided a broader answer Man 73 years from neuro surgery intermediate care ward, diagnosed with aspiration pneumonia ASTar reported ASTar ”resistant” t
Slide 10: True MIC matters: The MIC drives the choice of the optimal antimicrobial
True MIC matters: The MIC drives the choice of the optimal antimicrobial amongst those the pathogen is susceptible to Breakpoint S≤2 R>2 The further the MIC from its breakpoint, the lower the risk of Antibiotic X developing resistance. 0.12 0.25 0.50 1 2 4 8 16 32 MIC The antibiotic X has a MIC of 0
Slide 11: True MIC matters: MIC value can guide treatment for better patient outcome
True MIC matters: MIC value can guide treatment for better patient outcome Despite Staphylococcus Aureus is called susceptible to vancomycin for MIC values ≤2 (EUCAST), in clinical practice vancomycin is not used if MIC=2 because the risk of toxicity would increase significantly at the dosage requir
Slide 12: Health economic benefits of 24 hour faster diagnostics
Health economic benefits of 24 hour faster diagnostics Less pressure for Cost savings Lower mortality resistance and superinfections Up to 25% Up to 40% ~$2,500 – $20,000 reduction of C. difficile lower mortality rates1) cost savings per patient3) infections2) ASTar can provide 24-40 hour faster dia
Slide 13: Key highlights second quarter
Key highlights second quarter A very strong and important quarter ASTar receives CE-IVD for first product in May – Gram negative bacteria in BSI Excellent data Broad coverage Strong usability feedback US clinical study for ASTar started in June Q-linea will perform a major part of the study in-house
Slide 14: Key highlights second quarter – ASTar CE-IVD May 4th
Key highlights second quarter – ASTar CE-IVD May 4th Excellent and accurate data from the CE-IVD clinical study FDA and ISO requirements1,2) The ASTar® Instrument and ASTar® BC G- Kit offer the Essential agreement = Same MIC value as reference broadest combination of antimicrobials and dilution rang
Slide 15: Key highlights second quarter
Key highlights second quarter Successful directed share issue Gross proceeds of 301 million SEK Enable strengthening commercial activities Faster production capacity ramp-up activities Support product and geographical expansion Successful development of the portable culturing technology Fully autono
Slide 16: The effects of the Corona pandemic on Q-linea
The effects of the Corona pandemic on Q-linea A slow but steady move back to a more normal life… Q-linea has seen a decrease in Covid cases within the company and more employees have now been vaccinated. We have for the first time since the pandemic started been able to de-escalate some protective m
Slide 17: Income statement second quarter
Income statement second quarter Net sales in the second quarter amounted to SEK 4.3 million (0.1). Cost of Goods Sold and production costs SEK -9.3 (0) million includes a write off of total SEK -2,8 million Gross margin SEK -5,0 (0) million ; -117 (0) % Operating result totalled SEK -68.2 million (-
Slide 18: Balance sheet at the end of Q2
Balance sheet at the end of Q2 Cash and cash equivalents amounted to SEK 48.1 million (10.1) Short-term investments in fixed-income funds SEK 221,4 million (165,7) and the current portion of non-current assets (listed bonds) SEK 57.1 million (131.0). Non-current assets, listed bonds SEK 184.2 millio
Slide 19: Cash flow statement second quarter
Cash flow statement second quarter Cash flow from operating activities SEK -45.0 million (-54.8). Decrease in cash outflow from operating activities mainly due to an improvement in changes of the working capital that exceeded the larger operating result compared to the same quarter last year. Cash f
Slide 20: Thank you
Looking forward to an exciting continuation of 2021 Q-linea wants to contribute to a healthier society by future- proofing a new generation of healthcare professionals, labs and hospitals. Thank you 20